Control of physical forms of drug particles for pulmonary delivery by spray drying and supercritical fluid processing

KONA Powder and Particle Journal

Volumn 24, Issue March, 2006, Pages 27-40

  Tong, Henry H Y ^a   Chow, Albert H L ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

During particles; Physical forms; Pulmonary delivery; Spray drying; Supercritical fluids

Indexed keywords

EFFLUENT TREATMENT; SPRAY DRYING; SUPERCRITICAL FLUIDS;

CHEMICAL AND BIOLOGICALS; POLYMORPHIC TRANSFORMATION; PROCESSING TECHNOLOGIES; PROPERTIES OF THE POWDERS; PULMONARY DELIVERY; PULMONARY DRUG DELIVERY; SUPERCRITICAL FLUID PROCESSING; TECHNOLOGICAL DEVELOPMENT;

DRYING;

EID: 42049105704     PISSN: 02884534     EISSN: 21875537     Source Type: Journal    
DOI: 10.14356/kona.2006007     Document Type: Article

References (90)

1. Hickey, A.J.: "Inhalation Aerosols - Physical and Biological Basis for Therapy", Marcel Dekker Inc, New York (1996).
2. Agu, R.U., Ugwoke, M.I., Armand, M., Kinget, R. and Verbeke, N.: "The lung as a route for systemic delivery of therapeutic proteins and peptides", Respir. Res., 2: 198-209 (2001).
3. Bindra, S., Rosenstock, J. and Cefalu, W.T.: "Inhaled insulin: a novel route for insulin delivery", Expert. Opin. Inv. Drug, 11: 687-691 (2002).
4. Taburet, A.M. and Schmit, B.: "Pharmacokinetic optimization of asthma treatment", Clin. Pharmacokinet., 26: 396-418 (1994).
5. Langley, S.J., Sykes, A.P., Batty, E.P., Masterson, C.M. and Woodcock, A.: "A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients", Ann. Allerg. Asthma Im., 88: 488-493 (2002).
6. Taylor, J., Kotch, A., Rice, K., Ghafouri, M., Kurland, C.L., Fagan, N.A. and Witek, T.J.: "Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD", Chest, 120: 1253-1261 (2002).
7. Virchow, J.C., Kroegel, C. and Matthys, H.: "Antiasthma drug delivery: what is on the horizon", Clin. Pharmacokinet., 27: 85-93 (1994).
8. Byrn, S.R., Pfeiffer, R.R. and Stowell, J.G.: "Solid State Chemistry of Drugs (2nd edition)", SSCI Inc, West Lafayette, Indiana (1999).
9. Threlfall, T.: "Crystallization of polymorphs: Thermodynamic insight into the role of solvent", Org. Proc. Res. & Dev., 4: 384-396 (2000).
10. Borka, L.: "Review on crystal polymorphism of substances in the European Pharmacopoeia", Pharm. Acta. Helv., 66: 16-22 (1991).
11. Byrn, S. R., Pfeiffer, R. R., Stephenson, G., Grant, D. J. W. and Gleason, W. B.: "Solid state pharmaceutical chemistry", Chem. Mater., 6: 1148-1158 (1996).
12. Bauer, J., Spanton, S., Henry, R., Quick, J., Dziki, W., Porter, W. and Morris, J.: "Ritonavir: an extraordinary example of conformational polymorphism", Pharm. Res., 18: 859-866 (2001).
13. Haleblian, J. and McCrone, W.: "Pharmaceutical applications of polymorphism", J. Pharm. Sci., 58: 911-929 (1969).
14. Ikegami, K, Kawashima, Y., Takeuchi, H., Yamamoto, H., Isshiki, N., Momose, D. and Ouchi, K.: "Improved inhalation behavior of steroid KSR-592 in vitro with Jethaler by polymorphic transformation to needle-like crystals (β-form)", Pharm. Res., 19: 1439-1445 (2002).
15. Grant, D.J.W. and Higuchi, T.: "Solubility Behavior of Organic Compounds", John Wiley & Sons, New York (1990).
16. Brittain, H.G. and Fiese, E.F.: "Effects of pharmaceutical processing on drug polymorphs and solvates", In Brittain, H.G. Polymorphism in Pharmaceutical Solids. Marcel Dekker Inc, New York, USA (1999).
17. Kobayashi, Y., Ito, S., Itai, S. and Yamamoto, K.: "Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate", Int. J. Pharm., 193: 137-146 (2000).
18. Leung, S.S., Padden, B.E., Munson, E.J. and Grant, D.J.W.: "Hydration and dehydration behavior of aspartame hemihydrate", J. Pharm. Sci., 87: 508-513 (1997).
19. Khankari, R., Chen, L. and Grant, D.J.W.: "Physical characterization of nedocromil sodium hydrates", J. Pharm. Sci., 87: 1052-1061 (1998).
20. Rastogi, S., Zakrzewski, M. and Suryanarayanan, R.: "Investigation of solid-state reactions using variable temperature X-ray powder diffractometry. I. Aspartame hemihydrate", Pharm. Res., 18: 267-273 (2001).
21. Hanock, B.C. and Parks, M.: "What is the true solubility advantage for amorphous pharmaceuticals", Pharm. Res., 17: 397-404 (2000).
22. Hancock, B.C.: "Disordered drug delivery: destiny, dynamics and the Deborah number", The 138th British Pharmaceutical Conference, Glasgow, 23th-26th September (2001).
23. Beach, S., Latham, D., Sidgwick, C., Hanna, M. and York, P.: "Control of the physical form of salmeterol xinafoate", Org. Proc. Res. & Dev., 3: 370-376 (1999).
24. Kariuki, B.M, Psallidas, K., Harris, K.D.M., Johnston, R.L., Lancaster R.W., Staniforth S.E. and Cooper, S.M.: "Structure determination of a steroid directly from powder diffraction data", Chem. Commun., 17: 1677-1678 (1999).
25. Kawashima, Y., Serigano, T., Hino, T., Yamamoto, H. and Takeuchi, H.: "Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate", Int. J. Pharm., 172: 179-188 (1998).
26. ACGIH.: "Threshold limit values and biological exposure indices", ACGIH, Cincinnati, USA (1997).
27. Martin, A.: Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences (4th edition), Lea & Febiger, Philadelphia, USA (1993).
28. Stahl, K., Claesson, M., Lilliehorn, P., Linden, H. and Backstrom, K.: "The effects of process varib ales on the degradation and physical properties of spray dried insulin intended for inhalation", Int. J. Pharm., 233: 227-237 (2002).
29. Chawla, A., Taylor, K.M.G., Newton, J.M. and Johnson, M.C.R.: "Production of spray-dried salbutamol sulphate for use in dry powder aerosol formulation", Int. J. Pharm., 108: 233-240 (1994).
30. Dellamary, L.A., tarara, T.E., Smith, D.J., Woelk, C.H., Adractas, A., Costello, M.L., Gill, H. and Weers, J.G.: "Hollow porous particles in metered dose inhalers", Pharm. Res., 17: 168-174 (2000).
31. Duddu, S.P., Sisk, S.A., Walter, Y.H., Tarara, T.E., Trimble, K.R., Clark, A.R., Eldon, M.A., Elton, R.C., Pickford, M., Hirst, P.H., Newman, S.P. and Weers, J.G.: "Improved lung delivery from a passive dry powder inhaler using an engineered Pulmosphere ®powder", Pharm. Res., 19: 689-695 (2002).
32. Chew, N.Y.K. and Chan, H.K.: "Use of solid corrugated particles to enhance powder aerosol performance", Pharm. Res., 18: 1570-1577 (2001).
33. Vanbever, R., Mintzes, J. D., Wang, J., Nice, J., Chen, D., Batycky, R., Langer, R. and Edwards, D. A.: "Formulation and physical characterization of large porous particles for inhalation", Pharm. Res., 16: 1735-1742 (1999).
34. Hirst, P.H, Pitcairn, G.R., Weers, J.G., Tarara, T.E., Clark, A.R., Dellamary, L.A., Hall, G., Shorr, J. and Newman, S.P.: "In vivo deposition of hollow porous particles from a pressurized metered dose inhaler", Pharm. Res., 19: 258-264 (2002).
35. Lucas, P, Anderson, K., Potter, U.J. and Staniforth, J.N.: "Enhancement of small particle size dry powder aerosol formulations using an ultra low density additive", Pharm. Res., 16: 1643-1647 (1999).
36. Masters, L.: Spray Drying Handbook (5th edition), Longman, New York, USA (1991).
37. Columbano, A., Buckton, G. and Wikeley, P.: "A study of the crystallisation of amorphous salbutamol sulphate using water vapour sorption and near infrared spectroscopy", Int. J. Pharm., 237: 171-178 (2002).
38. Mu, L. and Feng, S.S.: "Fabrication, characterization and in vitro release of paclitaxel (Taxol®) loaded poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers", J. Control. Release, 76: 239-254 (2001).
39. Kimura, K., Hirayama, F., Arima, H. and Uekama, K.: "Effects of aging on crystallization, dissolution and absorption characteristics of amorphous tolbutamide- 2-hydroxypropyl-beta-cyclodextrin complex", Chem. Pharm. Bull., 48: 646-650 (2000).
40. Yonemochi, E., Kitahara, S., Maeda, S., Yamamura, S., Oguchi, T. and Yamamoto, K.: "Physicochemical properties of amorphous clarithromycin obtained by grinding and spray drying", Eur. J. Pharm. Sci., 7: 331-338 (1999).
41. Ueno, Y., Yonemochi, E., Tozuka, Y., Yamamura, S., Oguchi, T. and Yamamoto, K.: "Characterization of amorphous ursodeoxycholic acid prepared by spraydrying", J. Pharm. Pharmacol., 50: 1213-1219 (1998).
42. Chidavaenzi, O.C., Buckton, G., Koosha, F. and Pathak, R.: "The use of thermal techniques to assess the impact of feed concentration on the amorphous content and polymorphic forms present in spray dried lactose", Int. J. Pharm., 159: 67-74 (1997).
43. EsclusaDiaz, M.T., Guimaraens Mendez, M., Perez- Marcos, M.B., VilaJato, J.L. and TorresLabandeira, J.J.: "Characterization and in vitro dissolution behaviour of ketoconazole/beta- and 2-hydroxypropyl-betacyclodextrin inclusion compounds", Int. J. Pharm., 143: 203-210 (1996).
44. Beckmann, W. and Otto, W.H.: "Occurrence, stability, kinetics of crystallization and polymorphic transition of the A, B and C modification of abecarnil - Influence of supersaturation, temperature, solvents and impurities", Trans. IChemE. 74 (A): 750-758 (1996).
45. Yu, L. and Ng, K.: "Glycine crystallization during spray drying: the pH effect on salt and polymorphic forms", J. Pharm. Sci., 91: 2367-2375 (2002).
46. Kimura, K., Hirayama F. and Uekama, K.: "Charac terization of tolbutamide polymorphs (Burger's form II and IV) and polymorphic transition behaviour", J. Pharm. Sci., 88: 385-391 (1999).
47. Palakodaty, S and York, P.: "Phase behavioral effects on particle formation processes using supercritical fluids", Pharm. Res., 16: 976-985 (1999).
48. Shekunov, B.Y. and York, P.: "Crystallization processes in pharmaceutical technology and drug delivery design", J. Crystal Growth, 211: 122-136 (2000).
49. Jung, J. and Perrut, M.: "Particle design using supercritical fluids: Literature and patent survey", J. Supercrit. Fluid, 20: 179-219 (2001).
50. Tan, H.S., Borsadia, S.: "Particle formation using supercritical fluids: pharmaceutical applications", Expert. Opin. Ther. Pat., 11: 861-872 (2001).
51. Subramaniam, B., Rajewski, R.A. and Snavely, K.: "Pharmaceutical processing with supercritical carbon dioxide", J. Pharm. Sci., 86: 885-890 (1997).
52. Kiran, E., Debenedetti, P.G. and Peters, C.J.: Supercritical Fluids - Fundamentals and Applications, Kluwer Academic Publisher, Dordrecht, The Netherlands (2000).
53. Reverchon, E., Porta, G.D. and Taddeo, T.: "Solubility and micronization of griseofulvin in supercritical CHF3", Ind. Eng. Chem. Res., 34: 4087-4091 (1995).
54. Reverchon, E. and Donsi, G.: "Salicylic acid solubilization in supercritical CO2 and its micronization by RESS", J. Supercrit. Fluids, 6: 241-248 (1993).
55. Mohamed, R.S., Debenedetti, P.G. and Prud'homme, R.K.: "Effects of process conditions on crystals obtained from supercritical mixtures", AIChE. J., 35: 325-328 (1989).
56. Debenedetti, P.G.: "Homogeneous nucleation in supercritical fluids", AIChE. J., 36: 1289-1298 (1990).
57. Tom, J.W. and Debenedetti, P.G.: "Particle formation with supercritical fluids - A review", J. Aerosol Sci., 22: 555-584 (1991).
58. Debenedetti, P.G., Tom, J.W., Kwuak, X. and Yeo, S.D.: "Rapid expansion of superciritcal solutions (RESS): Fundamentals and applications", Fluid Phase Equilibria, 82: 311-321 (1993).
59. Kwauk, X. and Debenedetti, P.G.: "The mathematical modeling of aerosol formation by rapid expansion of supercritical solutions in a converging nozzle", J. Aerosol Sci., 24: 445-469 (1993).
60. Shaub, G.R., Brennecke, J.F. and McCready, M.J.: "Radial model for particle formation from the rapid expansion of supercritical solutions", J. Supercrit. Fluids, 8: 318-328 (1995).
61. Helfgen, B., Hils, P., Holzknecht, C., Turk, M. and Schaber, K.: "Simulation of particle formation during the rapid expansion of supercritical solutions", J. Aerosol Sci., 32: 295-319 (2001).
62. Gallagher, P.M., Coffey, M.P., Krukonis, V.J. and Klasutis, N.: "Gas antisolvent recrystllization: New process to recrystallize compounds insoluble in supercritical fluids. In: Supercritical Fluid Science and Technology", ACS Symposium Series 406; K. P. Johnston and J M. L. Penninger., Eds.; American Chemical Society: Washington, D. C., 334-354 (1989).
63. Bertucco, A., Pallado, P. and Benedetti, L.: "Formation of biocompatible polymer microspheres for controlled drug delivery by supercritical antisolvent technique". In: High Pressure Chemical Engineering, Process Technology Proceedings, 12, P. R. von Rohr and C. Trepp., Eds.; Elsevier, New York, 217-222 (1996).
64. Jaarmo, S., Rantakyla, M. and Aaltonen, O.: "Particle tailoring with supercritical fluid production of amorphous pharmaceutical particles", Proceedings of the 4th International Symposium on Supercritical Fluids, Sendai, Japan, 263-266 (1997).
65. Amaro-Gonzalez, D., Mabe, G., Zabaloy, M. and Brignole, E.A.: "Gas anti-solvent crystallization of organic salts from aqueous solutions", J. Supercrit. Fluids, 17: 249-258 (2000).
66. Dixon, D.J., Johnston, K.P. and Bodmeier, R.A.: "Polymeric material formed by precipitation with a compressed fluid antisolvent", AIChE. J., 39: 127-139 (1993).
67. Bodmeier, R., Wang, H., Dixon, D.J., Mawson, S. and Johnston, K.P.: "Polymeric microspheres prepared by spraying into compressed carbon dioxide", Pharm. Res., 12: 1211-1217 (1995).
68. Schmitt, W.J., Salada, M.C., Shook, G.G. and Speaker, S.M.: "Finely divided powders by carrier solution injection into a near or supercritical fluid", AIChE. J., 41: 2746-2786 (1995).
69. Lengsfeld, C.S., Delplanque, J.P., Barocas, V.H. and Randolph, T.W.: "Mechanism governing microparticle morphology during precipitation by a compressed antisolvent: atomization vs nucleation and growth", J. Phys. Chem. B, 104: 2725-2735 (2000).
70. Reverchon, E., Porta, G.D. and Pallado, P.: "Supercritical antisolvent precipitation of salbutamol microparticles", Powder Technology, 114: 17-22 (2001).
71. Chattopadhyay, P. and Gupta, R.B.: "Production of griseofulvin nanoparticles using supercritical CO2 antisolvent with enhanced mass transfer", Int. J. Pharm., 228: 19-31 (2001).
72. Bustami, R.T., Chan, H.K., Dehghani, F. and Foster, N.R.: "Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide", Pharm. Res., 17: 1360-1366 (2000).
73. Steckel, H. and Muller, B.W.: "Metered dose inhaler formulation of fluticasone-17-propionate micronized with supercritical fluid carbon dioxide using alternative propellant HFA-227", Int. J. Pharm., 173: 25-33 (1998).
74. Bleich, J., Kleinebudde, P. and Muller, B.W.: "Influence of gas density and pressure on microparticles produced with the ASES process", Int. J. Pharm., 106: 77-84 (1994).
75. York, P.: "Strategies for particle design using supercritical fluid technologies", Pharmaceutical Science and Technology Today, 2: 430-440 (1999).
76. Palakodaty, S., York, P. and Pritchard, J.: "Supercritical fluid processing of materials from aqueous solutions: The application of SEDS to lactose as a model substance", Pharm. Res., 15: 1835-1843 (1998).
77. Rehman, M., Shekunov, B.Y., York, P. and Colthorpe, P.: "Solubility and precipitation of nicotinic acid in supercritical carbon dioxide", J. Pharm. Sci., 90: 1570-1582 (2001).
78. Shekunov, B.Y., Hanna, M. and York, P.: "Crystallization process in turbulent supercritical fluid", J. Cryst. Growth, 198/199: 1345-1351 (1999).
79. Cooper, S.M.: "Orthorhombic crystalline form of fluticasone propionate and pharmaceutical composition thereof", United State Patent 6, 406, 718 (2002).
80. Gilbert, D. J., Palakodaty, S., York, P., Schultz, T. W. and Shah, D.: "Isolation of the polymorphic forms of RWJ-337813 using the solution enhanced dispersion by the supercritical fluids (SEDS) technique", AAPSPharmSci., 3 (3) (2001).
81. Vemavarapu, C., Mollan, M. J., Ghebre-Sellassie, I. and Needham, T. E.: "Crystal engineering of chlorpropamide by recrystallization from supercritical solutions", AAPSPharmSci., 3 (3) (2001).
82. Reverchon, E., Porta, G.D. and Falivene, M.G.: "Process parameters controlling the supercritical antisolvent micronization of some antibiotics", Proceedings of the 6th meeting on supercritical fluids, Supercritical fluids chemistry and materials, held on 10-13 April, Nottingham, United Kingdom (1999).
83. Hanna, M. and York, P.: "Method and apparatus for the formation of particles", International Patent Publication Number WO 96/00610 (1996).
84. Velaga, S.P., Berger, R. and Carlfors, J.: "Supercritical fluids crystallization of budesonide and flunisolide", Pharm. Res., 19: 1564-1571 (2002).
85. Tong, H.H.Y.: "Comparative studies on the physical and surface properties of salmeterol xinafoate prepared by spray-drying and supercritical fluid processing", Ph.D. thesis, Chinese University of Hong Kong (2003).
86. Bisrat, M., Moshashaee, S., Nyqvist, H.K. and Demirbuker, M.: "Crystallization using supercritical or subcritical fluids", United States Patent 6, 461, 642 (2002).
87. Bristow, S., Cocks, P.M., Harland, R. and Gandhi, R.B.: "Stavudine polymorphic form I process", International Patent Publication Number WO 02/20538 A2 (2002).
88. Edwards, A.D., Shekunov, B.Y., Kordikowski, A., Forbes, R. and York, P.: "Crystallization of pure anhydrous polymorphs of carbamazepine by solution enhanced dispersion with supercritical fluids (SEDSTM)", J. Pharm. Sci., 90: 1115-1124 (2001).
89. Rehman, M.U.: "The design and characterisation of particles of inhalation compounds prepared using supercritical fluid crystallisation", Ph.D. thesis, University of Bradford (2002).
90. Kordikowski, A., Shekunov, T. and York, P.: "Polymorph control of sulfathiazole in supercritical CO2", Pharm. Res., 18: 682-688 (2001).